Sanofi Pasteur MSD's recombinant quadrivalent human papillomavirus (HPV) vaccine [Gardasil] has been launched in 15 EU countries

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1575, 2007-01, pp. : 23-23

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Human Papillomavirus Quadrivalent (types 6, 11, 16, 18) Recombinant Vaccine (Gardasil ® )

By Siddiqui M. Asif A.   Perry Caroline M.  

Drugs, Vol. 66, Iss. 9, 2006-01 ,pp. : 1263-1271

Adis International

Access to resources Recommend Favorite

Human Papillomavirus Quadrivalent (types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®): A Viewpoint by Daron G. Ferris

By Ferris Daron G.  

Drugs, Vol. 66, Iss. 9, 2006-01 ,pp. : 1272-1273

Adis International

Access to resources Recommend Favorite

Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®): A Review of its Use in the Prevention of Premalignant Genital Lesions, Genital Cancer and Genital Warts in Women

By McCormack Paul L.  

Drugs, Vol. 70, Iss. 18, 2010-12 ,pp. : 2449-2474

Adis International

Access to resources Recommend Favorite

Human papillomavirus vaccine recombinant quadrivalent: Brachial plexus neuritis: case report

By  

Reactions Weekly, Vol. 1, Iss. 1218, 2008-01 ,pp. : 18-19

Adis International

Access to resources Recommend Favorite

Human papillomavirus vaccine recombinant quadrivalent: Subcutaneous emphysema: case report

By  

Reactions Weekly, Vol. 1, Iss. 1261, 2009-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite